EIA COVID-19 RBD IgA CE-IVD
The immunoenzymatic assay - EIA COVID-19 RBD (Receptor Binding Domain) IgA - is intended for the diagnosis, monitoring and screening SARS-CoV-2 (COVID-19) infection using IgA antibodies in human serum, plasma or dry blood spot in the general population.
The semi-quantitative and quantitative manual assay is designed for professional use in a laboratory.
The kit is intended for detection of specific IgA antibodies in a sample by means of a sandwich type of the EIA method.
Downloads
Hey, it seems that you’re connected from United States.
For registration requirements in countries outside of European market, please contact regulatory.affairs@diasource.be.